Human Tissue and Sample Acquistion

本计划的主要目标是对稳态和器官移植中人类淋巴样细胞和粘膜组织中的淋巴细胞和先天淋巴样细胞群进行新的分析，以阐明以前未探索的人体全身免疫反应的新方面。我们将在这个项目中使用两种人体组织来源：已故器官捐赠者和接受移植的患者。项目1-3将检测T， B和先天淋巴样细胞（ILC）在多个组织中获得。项目4将描述肠道移植中的淋巴细胞和ILC群体。对于所有的项目来说，获取人体组织是必不可少的。人体组织和样本采集核心将负责协调所有人员、机构保障、协议和MTAs，以获取和处理人体组织，并向所有四个项目分发样本。这个核心将在项目的所有年份发挥作用，因为它对整个项目至关重要。这个基本核心将根据人体组织样本的两个主要来源分为两个部分。在第一部分中，核心将获得并处理来自人体器官供体的多种淋巴组织和粘膜组织。我们已经与CUMC的外科医生和纽约器官捐赠网络（NYODN）建立了必要的协议和合作，以从研究同意的器官捐赠者那里获得不用于挽救生命的移植的组织。对于这部分核心，我们将协调从近亲同意使用组织进行研究的器官捐献者处获取多种淋巴组织和粘膜组织。组织将在实验室处理，细胞悬液、整个组织和组织支架将分发到所有项目实验室（项目1-4）。对于核心的第二部分，我们将协调从移植患者获得活检和外周血样本。我们将获得肠移植患者的活检和外周血标本，这些患者将被纳入项目4的相关研究。该核心的人员将维护IRB方案以获取样本，在本研究中招募患者，将与临床医生合作获取活检和血液样本，作为其临床管理的一部分，协调将其分发给项目4的研究人员以表征T细胞重构和同种异体反应性，并将其分发给CCTI生物库进行处理和储存。

The main goal of this program is to conduct a novel analysis of lymphocyte and innate lymphoid cell populations in human lymphoid and mucosal tissues in steady state and in organ transplantation, to elucidate novel aspects of human immune responses in the whole body that have not previously been explored. We will use two sources of human tissues for this program: deceased organ donors and transplant patients. Projects 1-3 will examine T, B and innate lymphoid cells (ILC) in multiple tissues obtained from . organ donors, and Project 4 will characterize lymphocyte and ILC populations in intestinal transplants. For all of the projects, the acquisition of human tissues is essential. The human tissue and sample acquisition core will be responsible for coordinating all ofthe personnel, institutional assurance, protocols and MTAs necessary to acquire and process human tissues, and distribute samples to all four projects. This core will function for all years of the project as it is essential to the entire program. This essential core will be divided into two parts based on the two main sources of human tissue samples. In the first part, the core will obtain and process multiple lymphoid and mucosal tissues from human organ donors. We have established the necessary protocols and collaborations with CUMC surgeons and the New York Organ Donor network (NYODN) to obtain from research-consented organ donors, tissues that are not used for life-saving transplantation. For this part of the core, we will coordinate the acquisition of multiple lymphoid tissues and mucosal tissues from organ donors whose next-of-kin have consented for use of tissues for research. The tissues will be processed in the laboratory and cell suspensions, whole tissues and tissue mounts will be distributed to all project laboratories (Projects 1-4). For the second part ofthe core, we will coordinate the acquisition of biopsy and peripheral blood samples from transplant patients. We will obtain biopsy and peripheral blood specimens from intestinal transplant patients who will be enrolled in studies related to Project 4. The personnel in this core will maintain IRB protocols for obtaining samples, enroll patients in this study, will work with the clinicians to obtain biopsy and blood samples as part of their clinical management, coordinate their distribution to Project 4 investigators for the characterization of T cell reconstitufion and alloreactivity, and to the CCTI Biobank for processing and storage.